Trial Profile
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary) ; Temozolomide
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2017 Planned End Date changed from 30 Jun 2019 to 31 Oct 2019.